Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
4.110
-0.140 (-3.29%)
At close: Jun 27, 2025, 4:00 PM
4.140
+0.030 (0.73%)
After-hours: Jun 27, 2025, 7:53 PM EDT
Skye Bioscience Employees
Skye Bioscience had 16 employees as of December 31, 2024. The number of employees increased by 5 or 45.45% compared to the previous year.
Employees
16
Change (1Y)
5
Growth (1Y)
45.45%
Revenue / Employee
n/a
Profits / Employee
-$2,040,682
Market Cap
127.35M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
SKYE News
- 5 days ago - Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions - GlobeNewsWire
- 11 days ago - Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions - GlobeNewsWire
- 5 weeks ago - Skye Bioscience to Participate in Upcoming Investment Conferences - GlobeNewsWire
- 5 weeks ago - Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab - GlobeNewsWire
- 6 weeks ago - Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity - GlobeNewsWire
- 7 weeks ago - Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity - GlobeNewsWire